Do Probiotics Help Hay Fever? Better Than Placebo, Unproven vs. Antihistamines

Multispecies probiotics may ease hay fever symptoms a little more than placebo. What they cannot yet do is answer the question that matters at the pharmacy counter: how do they compare with a standard antihistamine?

Two randomized, double-blind, placebo-controlled trials tested different oral probiotic mixtures for seasonal allergic rhinitis. Both found a broadly favorable signal, but neither established that a probiotic delivers a clinically meaningful benefit in a way that would justify replacing first-line treatment. Neither included cetirizine, loratadine, or an intranasal corticosteroid as an active comparison.

That omission leaves a large practical gap. A supplement can beat placebo and still be less useful than a cheap antihistamine. It might also help as an add-on. Current trials do not tell us which.

Two trials, similar direction, different problems

The more detailed positive trial was a 2022 Melbourne pollen-season trial by Ried et al. Participants took one 1.5 g sachet daily for 12 weeks containing four strains: Lactobacillus reuteri GL-104, L. rhamnosus MP-108, Bifidobacterium lactis BI04, and L. plantarum LPL28. The daily total was 10 billion CFU.

The investigators tracked Total Nasal Symptom Score (TNSS) and the modified Rhinoconjunctivitis Quality of Life Questionnaire (mRQLQ), using pollen-peak-adjusted weekly assessments. The probiotic group had statistically significant improvements in those measures in subgroup analyses adjusted for pollen peaks. The full intention-to-treat population did not produce those significant findings.

That distinction matters. Subgroup results can generate a useful hypothesis, especially during a variable pollen season, but they carry less weight than a pre-specified result in all randomized participants. About half of participants dropped out, which further weakens confidence in the estimate and raises the risk that the favorable analyses overstate the effect. The supplement manufacturer supplied the product, and this particular formula has not received an independent academic replication in the evidence discussed here.

A 2023 randomized trial by Cox et al. tested a different multispecies probiotic in adults with confirmed Bermuda Grass allergy. Participants received 4 billion CFU per day in two doses or placebo for eight weeks. Of 165 randomized adults, 142 were analyzed. Its pre-specified primary endpoint was the share of participants who improved by more than 0.7 points on the mRQLQ, the trial's threshold for a clinically meaningful change.

The result was flat: 61% of the probiotic group and 62% of the placebo group crossed that threshold (p = 0.90). The published abstract does not disclose the strains, so readers cannot compare its formula directly with Ried's four-strain product.

The null result also has an unusual design problem. Before supplements began, 76 of 165 participants—46%—had already crossed the same 0.7-point mRQLQ threshold between screening and day 0. Seasonal symptoms can move quickly with pollen exposure, weather, and timing. When nearly half a sample has already met the improvement threshold before treatment, that endpoint leaves little room to separate treatment from placebo. This does not show that the probiotic formula worked; it means the trial's primary endpoint could not give a clean answer about whether it worked.

Meta-analyses support a modest average effect, not a product recommendation

The individual trials sit within a larger, but messy, literature. A 2022 systematic review and meta-analysis by Luo et al. found statistically significant overall improvements in allergic-rhinitis symptom scores with probiotics. The authors also found substantial differences among studies in strain identity, dose, duration, allergen exposure, and outcome measures. Small trials made the pooled estimate less secure.

A separate 2022 meta-analysis of 26 pediatric randomized trials also found significant but modest pooled effects. That supports the idea that probiotics can influence allergic-rhinitis outcomes across studies, but children are not interchangeable with adults. It does not validate a particular adult product, dose, or treatment schedule.

High heterogeneity has a plain-English consequence: "probiotics" is too broad to act like the name of one medicine. A four-strain sachet at 10 billion CFU for 12 weeks and an undisclosed mixture at 4 billion CFU for eight weeks are different interventions. Pooling them can reveal a direction of effect, but it cannot tell a buyer which bottle deserves their money.

The biology is plausible, but it has not settled the clinical question

Several human trials offer potential explanations for a modest effect. A 2024 double-blind synbiotic trial by Hou et al. linked improved seasonal allergic-rhinitis symptom scores with changes in intestinal Clostridiales/Bacteroidales ratios and short-chain-fatty-acid metabolic pathways. Those findings fit a gut-to-immune pathway, but they do not prove that microbiome changes caused the symptom changes.

A 2025 randomized trial of B. animalis subsp. lactis A6 in adults with perennial allergic rhinitis reported lower serum total IgE and IL-13. Ried's formula also included a B. lactis strain, but sharing a genus does not make two strains clinically equivalent. Biomarker shifts support biological plausibility; they do not establish symptom relief for another formula.

The route of action remains unsettled. A 2022 crossover trial of a nasal probiotic assemblage found no significant symptom benefit and no detectable changes in several nasal-lavage cytokines. Direct nasal application, at least with that assemblage and protocol, did not work.

Yet a 2025 study of oral L. rhamnosus GG chewables found nasal colonization and local immune signals in people with allergic rhinoconjunctivitis. Its primary outcomes were not clinical symptom efficacy. Together, these studies argue against a tidy one-pathway story: oral probiotics may affect systemic immune signaling, nasal mucosa, or both, depending on the strain, delivery method, and person.

Why antihistamines remain the benchmark

The probiotic trials used placebo comparators, which answer a narrow question: did the tested supplement outperform an inert look-alike under those conditions? They did not test whether probiotics match standard care, add to it, or allow anyone to use less of it.

That makes indirect comparisons a poor substitute for a direct trial. The mRQLQ threshold in the Cox study was more than 0.7 points, but no head-to-head study in this evidence base has placed a probiotic and a second-generation antihistamine on the same scale, in the same pollen season, against the same placebo. The absence is especially conspicuous because standard antihistamines are inexpensive and widely available.

A probiotic can be biologically plausible and statistically better than placebo without being a replacement for an antihistamine.

What a useful next trial would look like

A definitive study should enroll people with confirmed allergen sensitization, randomize them at pollen-season onset after a 72-hour symptom run-in, and adjust its primary analysis for daily pollen counts. It should run for at least 12 weeks and compare four groups: probiotic, antihistamine, probiotic plus antihistamine, and placebo.

The proposed size is roughly 200 to 250 participants per group to detect a 0.5-point mRQLQ difference with 80% power, assuming a standard deviation near 1.2. That design would answer the clinically relevant questions: whether probiotics provide meaningful relief alone, whether they improve standard treatment, and whether apparent benefits exceed ordinary seasonal fluctuation.

Verdict

Oral multispecies probiotics have a consistent enough placebo-controlled signal to merit further study, and pooled analyses suggest the average effect is modestly favorable. The best-characterized seasonal formula combined L. rhamnosus, B. lactis, L. reuteri, and L. plantarum at 10 billion CFU daily for 12 weeks, but its positive results came from subgroup analyses in a trial with heavy dropout.

For someone already using an antihistamine, a probiotic is a plausible but unproven adjunct. For someone considering replacing standard treatment, the evidence does not support that move. The missing comparison is not a technicality; it is the whole decision.